T. Rowe Price Associates
SCR

T. Rowe Price Associates’s SIMCERE PHARMACEUTICAL GROUP, ADS SCR Stock Holding History

T. Rowe Price Associates’s Portfolio SCR Stock Details SCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-599,300
Closed -$5.67M – 2550
2013
Q3 		$5.67M Hold
599,300
– – ﹤0.01% 1401
2013
Q2 		$5.68M Buy
+599,300
New +$5.54M ﹤0.01% 1384

Other funds holding SCR

SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

T. Rowe Price Associates's SCR Position: Q4 2013 in Review

T. Rowe Price Associates sold out of SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) in Q4 2013, closing a stake of 599,300 shares — an estimated $5.67M sold.

T. Rowe Price Associates first reported a position in SCR in Q2 2013 and held it in 2 quarters. The position peaked at $5.68M in Q2 2013. 12 funds tracked by Wall St. Rank hold SCR as of Q4 2013.

  • T. Rowe Price Associates reported no remaining SIMCERE PHARMACEUTICAL GROUP, ADS position as of Q4 2013 after selling out during the quarter.
  • T. Rowe Price Associates sold 599,300 SIMCERE PHARMACEUTICAL GROUP, ADS shares in Q4 2013, an estimated $5.67M.
  • T. Rowe Price Associates first reported a position in SIMCERE PHARMACEUTICAL GROUP, ADS in Q2 2013 and held it in 2 quarters.
  • T. Rowe Price Associates's SIMCERE PHARMACEUTICAL GROUP, ADS position peaked at $5.68M in Q2 2013.
  • 12 funds tracked by Wall St. Rank held SIMCERE PHARMACEUTICAL GROUP, ADS as of Q4 2013.

Based on T. Rowe Price Associates's 13F filing for Q4 2013, filed 14 Feb 2014.